News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
FDA Approves Repatha for Pediatric Heterozygous Familial Hypercholesterolemia
The FDA has granted approval for Repatha, a groundbreaking treatment for pediatric patients suffering from heterozygous familial hypercholesterolemia, enhancing cholesterol control.
FDA Approves Adzynma: New Treatment for Thrombotic Thrombocytopenic Purpura
Adzynma has received FDA approval as a new treatment for Thrombotic Thrombocytopenic Purpura, marking a significant advancement in patient care.
FDA Approves First OTC Naloxone Nasal Spray for Opioid Overdose
In a groundbreaking move, the FDA has approved the first over-the-counter naloxone nasal spray, providing a critical tool in combating opioid overdose emergencies.
FDA Grants Priority Review to Sotorasib for KRAS G12C NSCLC
Sotorasib receives FDA priority review for KRAS G12C non-small cell lung cancer (NSCLC), marking a pivotal step in targeted cancer treatment.
FDA Approves Veozah: New Non-Hormonal Menopause Treatment
Veozah, recently approved by the FDA, provides a non-hormonal option for managing menopause symptoms, marking a significant advancement in women's health.
FDA Approves Omisirge: New Allogeneic Stem Cell Therapy for Hematologic Cancers
The FDA has approved Omisirge, an innovative allogeneic stem cell therapy designed to treat hematologic cancers, marking a significant advancement in cancer care.
FDA Approves Updated COVID-19 Vaccines for Fall 2024
The FDA has approved updated COVID-19 vaccines for Fall 2024, aimed at improving immunity against new variants and safeguarding community health.
FDA Approves Bosulif for Pediatric Chronic Myelogenous Leukemia
Bosulif has received FDA approval for the treatment of pediatric chronic myelogenous leukemia, marking a significant advancement in pediatric oncology.
FDA Approves Ztalmy: First Therapy for CDKL5 Deficiency Seizures
Ztalmy has received FDA approval as the first treatment for CDKL5 deficiency seizures, marking a significant advancement in managing this rare genetic disorder.
FDA Approves Opdivo Plus Chemotherapy for Gastric Cancer
The FDA has approved Opdivo in combination with chemotherapy for the treatment of gastric cancer, marking a significant advancement in cancer care.
FDA Approves Breyanzi: Novel CAR-T Therapy for Mantle Cell Lymphoma
Breyanzi has received FDA approval as a novel CAR-T therapy, providing a promising treatment option for patients with mantle cell lymphoma.
FDA Approval Mirvetuximab Soravtansine: Accelerated OK for Elahere in Ovarian Cancer
The FDA has granted accelerated approval for Mirvetuximab Soravtansine, branded as Elahere, offering new hope for patients with ovarian cancer.
FDA Approves Elarek: New Option for Osteoporosis Prevention
Elarek has received FDA approval as a new preventive treatment for osteoporosis, marking a significant advancement in bone health management.
FDA Approves First Interchangeable Biosimilar for Stelara (Ustekinumab)
The FDA has approved the first interchangeable biosimilar for Stelara (Ustekinumab), expanding treatment options for patients with psoriasis and Crohn's disease.
FDA Approves Novel Anti-Inflammatory Drug for Atopic Dermatitis Treatment
The FDA has approved Dermacure, a novel anti-inflammatory drug, to treat atopic dermatitis, promising significant relief for patients suffering from this chronic skin condition.
FDA Approves Amgen's Bispecific Antibody for Metastatic Colorectal Cancer
The FDA has approved Amgen's bispecific antibody, providing a new treatment option for patients battling metastatic colorectal cancer.
FDA Approves Syfovre: First Treatment for Geographic Atrophy
Syfovre has received FDA approval as the first-ever treatment for geographic atrophy, marking a significant advancement in managing this debilitating condition.
FDA Approves EndeavorRx: First Digital Therapeutic for Adult ADHD
EndeavorRx, now FDA-approved, is the first digital therapeutic designed specifically for adults with ADHD, revolutionizing treatment options.
FDA Approves Roche's NTRK Fusion Therapy for Solid Tumors
Roche's NTRK Fusion Therapy receives FDA approval, marking a significant advancement in the treatment of solid tumors with NTRK gene fusions.
FDA Approves First CRISPR Gene Therapy for Sickle Cell Disease
The FDA has approved Zynteglo, the first CRISPR gene therapy for sickle cell disease, offering new hope for patients with this debilitating condition.